RT Journal Article
SR Electronic
T1 Fibrinogen does not relate to cardiovascular or muscle manifestations in COPD: cross-sectional data from the ERICA study
JF Thorax
JO Thorax
FD BMJ Publishing Group Ltd and British Thoracic Society
SP 1182
OP 1185
DO 10.1136/thoraxjnl-2018-211556
VO 73
IS 12
A1 Divya Mohan
A1 Julia R Forman
A1 Matthew Allinder
A1 Carmel M McEniery
A1 Charlotte Emma Bolton
A1 John R Cockcroft
A1 William MacNee
A1 Jonathan Fuld
A1 Mellone Marchong
A1 Nichola Sian Gale
A1 Marie Fisk
A1 Sridevi Nagarajan
A1 Joseph Cheriyan
A1 David A Lomas
A1 Peter M A Calverley
A1 Bruce E Miller
A1 Ruth Tal-Singer
A1 Ian B Wilkinson
A1 Michael I Polkey
A1 ,
YR 2018
UL http://thorax.bmj.com/content/73/12/1182.abstract
AB Cardiovascular and skeletal muscle manifestations constitute important comorbidities in COPD, with systemic inflammation proposed as a common mechanistic link. Fibrinogen has prognostic role in COPD. We aimed to determine whether aortic stiffness and quadriceps weakness are linked in COPD, and whether they are associated with the systemic inflammatory mediator—fibrinogen. Aortic pulse wave velocity (aPWV), quadriceps maximal volitional contraction (QMVC) force and fibrinogen were measured in 729 patients with stable, Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages II–IV COPD. The cardiovascular and muscular manifestations exist independently (P=0.22, χ2). Fibrinogen was not associated with aPWV or QMVC (P=0.628 and P=0.621, respectively), making inflammation, as measured by plasma fibrinogen, an unlikely common aetiological factor.